Astrana Health, Inc. experienced substantial revenue growth in Q4 2024, with total revenue increasing by 88% year-over-year, primarily driven by a 98% increase in Care Partners revenue; however, the company reported a net loss of $7.0 million for the quarter, compared to a net income in the prior year period.
Total revenue for Q4 2024 increased by 88% to $665.2 million, up from $353.0 million in Q4 2023.
Care Partners revenue grew by 98% to $647.7 million in Q4 2024, compared to $326.8 million in Q4 2023.
The company reported a net loss attributable to Astrana of $7.0 million in Q4 2024, a decline from a net income of $12.4 million in Q4 2023.
Adjusted EBITDA for Q4 2024 increased by 21% to $35.0 million, up from $29.0 million in Q4 2023.
For 2025, Astrana Health, Inc. projects total revenue between $2.5 billion and $2.7 billion, and Adjusted EBITDA between $170 million and $190 million, based on existing business and market conditions, including strategic investments in automation and AI, and integration costs from planned acquisitions.
Analyze how earnings announcements historically affect stock price performance